1-1 of 1
John Gericitano, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and Antitumor Efficacy of the Proteasome Inhibitor Carfilzomib (PR-171) Dosed for Five Consecutive Days in Hematologic Malignancies: Phase 1 Results.

Robert Z. Orlowski, MD, PhD, Keith Stewart, MD, Marcy Vallone, Chris Molineaux, Lori Kunkel, MD, John Gericitano, MD, Owen A. O’Connor, MD
Journal: Blood
Blood (2007) 110 (11): 409.
https://doi.org/10.1182/blood.V110.11.409.409
Published: 2007